Chemoproteomic-enabled characterization of small GTPase Rab1a as a target of an N -arylbenzimidazole ligand's rescue of Parkinson's-associated cell toxicity.

Journal Article (Journal Article)

The development of phenotypic models of Parkinson's disease (PD) has enabled screening and identification of phenotypically active small molecules that restore complex biological pathways affected by PD toxicity. While these phenotypic screening platforms are powerful, they do not inherently enable direct identification of the cellular targets of promising lead compounds. To overcome this, chemoproteomic platforms like Thermal Proteome Profiling (TPP) and Stability of Proteins from Rates of Oxidation (SPROX) can be implemented to reveal protein targets of biologically active small molecules. Here we utilize both of these chemoproteomic strategies to identify targets of an N -arylbenzimidazole compound, NAB2, which was previously identified for its ability to restore viability in cellular models of PD-associated α-synuclein toxicity. The combined results from our TPP and SPROX analyses of NAB2 and the proteins in a neuroblastoma-derived SHSY5Y cell lysate reveal a previously unrecognized protein target of NAB2. This newly recognized target, Rab1a, is a small GTPase that acts as a molecular switch to regulate ER-to-Golgi trafficking, a process that is disrupted by α-synuclein toxicity and restored by NAB2 treatment. Further validation reveals that NAB2 binds to Rab1a with selectivity for its GDP-bound form and that NAB2 treatment phenocopies Rab1a overexpression in alleviation of α-synuclein toxicity. Finally, we conduct a preliminary investigation into the relationship between Rab1a and the E3 ubiquitin ligase, Nedd4, a previously identified NAB2 target. Together, these efforts expand our understanding of the mechanism of NAB2 in the alleviation of α-synuclein toxicity and reinforce the utility of chemoproteomic identification of the targets of phenotypically active small molecules that regulate complex biological pathways.

Full Text

Duke Authors

Cited Authors

  • Hatstat, AK; Quan, B; Bailey, MA; Fitzgerald, MC; Reinhart, MC; McCafferty, DG

Published Date

  • January 2022

Published In

Volume / Issue

  • 3 / 1

Start / End Page

  • 96 - 111

PubMed ID

  • 35128413

Pubmed Central ID

  • PMC8729260

Electronic International Standard Serial Number (EISSN)

  • 2633-0679

International Standard Serial Number (ISSN)

  • 2633-0679

Digital Object Identifier (DOI)

  • 10.1039/d1cb00103e


  • eng